Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
10.5415/apallergy.2019.9.e7
- Author:
Sankei NISHIMA
1
;
Masanari KOZAWA
;
Ki Lee MILLIGAN
;
Nikolaos G PAPADOPOULOS
Author Information
1. National Hospital Organization, Fukuoka National Hospital, Fukuoka, Japan. nishima.sankei.ac@mail.hosp.go.jp
- Publication Type:Review
- Keywords:
Biologicals;
Therapeutic guidelines;
Japan;
Omalizumab;
Pediatric asthma
- MeSH:
Asian Continental Ancestry Group;
Asthma;
Child;
Comorbidity;
Dermatitis, Atopic;
Food Hypersensitivity;
Humans;
Japan;
Omalizumab;
Rhinitis, Allergic
- From:
Asia Pacific Allergy
2019;9(1):e7-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Childhood asthma is one condition within a family of allergic diseases, which includes allergic rhinitis, atopic dermatitis, and food allergy, among others. Omalizumab is an anti-IgE antibody therapy that was approved in Japan for children with asthma and added to the Japanese pediatric asthma guidelines in 2017. This review highlights the Japanese clinical perspectives in pediatric allergic asthma, and consideration for allergic comorbidities, and reflects on omalizumab clinical trials in progress to present comprehensive future opportunities.
